SCR-LIP-000543 · Claim · machine-readable JSON →

Histological and molecular analysis identified distinguishing features among lipedema, lipohypertrophy, and secondary lymphedema, including VEGF-R3, GJA1/Connexin-43 and Claudin-5 upregulation exclusive to lymphedema, adipocyte hypertrophy in lipedema and lipohypertrophy, and dramatically reduced podoplanin lymphatic coverage in lipohypertrophy.

Retired in the claim consolidation (R-CLM-19): its source was judged not to be a finding on any question (e.g. a protocol, a truncated abstract or an off-topic paper). Kept for the record; see the change log below.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
low (GRADE)
Evidence
1 source(s)
Dates
2026-11-17 → 2026-11-17

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17

Evidence over time

2023A Comparative Analysis to Dissect the Histological and Molecular Differences among Lipedema, Lipohypertrophy and Secondary Lymphedema (2023) · contextual

Evidence (1)

Context (PECO)

Populationpatients with lipedema, lipohypertrophy, secondary lymphedema, and healthy controls
Conditionlipedema
Exposurehistological and molecular tissue profiling (histology, IHC, qPCR)
Comparatoracross conditions vs healthy controls
Outcomedistinguishing histological/molecular biomarkers
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log